Quarterly ResultMay 6, 2026, 05:22 PM
ADMA Biologics Q1 Net Income $45.3M, EPS $0.19; $130.2M Buyback
AI Summary
ADMA Biologics reported strong financial performance for Q1 2026, with net income increasing to $45.3 million and diluted EPS rising to $0.19, despite a slight dip in revenues. The company significantly improved its gross profit and income from operations, and generated substantial positive cash flow from operating activities. Additionally, ADMA completed the sale of three plasma collection centers, recognizing an $8.0 million gain, and executed a $130.2 million treasury stock acquisition.
Key Highlights
- Net income for Q1 2026 was $45.3 million, up from $26.9 million in Q1 2025.
- Diluted earnings per common share increased to $0.19 in Q1 2026 from $0.11 in Q1 2025.
- Gross profit rose to $80.8 million in Q1 2026, compared to $61.1 million in Q1 2025.
- Revenues for Q1 2026 were $114.5 million, a slight decrease from $114.8 million in Q1 2025.
- Net cash provided by operating activities was $58.2 million in Q1 2026, a significant improvement from $(19.7) million used in Q1 2025.
- Recognized an $8.0 million gain on the sale of three plasma collection centers in Q1 2026.
- Acquired $130.2 million in treasury stock during Q1 2026.
- Drew $125.0 million from the JPM revolving credit facility in Q1 2026.
Price Impact
More from ADMA